Selected article for: "duration symptom severity and symptom severity"
Author: Lee, Chang-Seop; Lee, Ju-Hyung; Oh, Mira; Choi, Kyung-Min; Jeong, Mi Ran; Park, Jong-Dae; Kwon, Dae Young; Ha, Ki-Chan; Park, Eun-Ock; Lee, Nuri; Kim, Sun-Young; Choi, Eun-Kyung; Kim, Min-Gul; Chae, Soo-Wan
Title: Preventive Effect of Korean Red Ginseng for Acute Respiratory Illness: A Randomized and Double-Blind Clinical Trial
  • Document date: 2012_12_7
    • ID: v07crluc_16
    Snippet: The ARI defined by following symptoms; fever (temperature > 38.0°C), cough, sore throat, nasal congestion, or body aches in the absence of a known cause other than influenza. The primary efficacy end point was the frequency rate of ARI. The secondary end point included 1) the frequency rate of each clinical symptoms such as fever, rhinorrhea, nasal congestion, sore throat, cough, sputum, dyspnea, diarrhea, nausea, vomiting, headache, and myalgia.....
    Document: The ARI defined by following symptoms; fever (temperature > 38.0°C), cough, sore throat, nasal congestion, or body aches in the absence of a known cause other than influenza. The primary efficacy end point was the frequency rate of ARI. The secondary end point included 1) the frequency rate of each clinical symptoms such as fever, rhinorrhea, nasal congestion, sore throat, cough, sputum, dyspnea, diarrhea, nausea, vomiting, headache, and myalgia 2) symptom duration; and 3) severity of symptom (total symptom score).

    Search related documents:
    Co phrase search for related documents
    • body ache and nasal congestion: 1
    • body ache and sore throat: 1, 2, 3, 4, 5, 6, 7
    • body ache nasal congestion and nasal congestion: 1
    • body ache nasal congestion and sore throat: 1
    • body ache nasal congestion sore throat and nasal congestion: 1
    • body ache nasal congestion sore throat and sore throat: 1
    • clinical symptom and frequency rate: 1
    • clinical symptom and nasal congestion: 1, 2, 3, 4, 5
    • clinical symptom and primary efficacy: 1, 2
    • end point and primary efficacy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33
    • end point and primary efficacy end: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26
    • end point and primary efficacy end point: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
    • end point and secondary end point: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46
    • frequency rate and nasal congestion: 1
    • frequency rate and primary efficacy: 1
    • nasal congestion and primary efficacy: 1
    • primary efficacy and secondary end point: 1, 2, 3, 4
    • primary efficacy end and secondary end point: 1, 2, 3
    • primary efficacy end point and secondary end point: 1, 2